Drug facts

Tirzepatide, anxiety and mood

Reviewed August 2026

What the label says about mood: nothing¹

The words that would settle this are anxiety, depression, depressive, mood, psychiatric, suicidal, suicide, irritability and panic. Every section of both approved labels was read for them, including the boxed warning, warnings and precautions, adverse reactions, use in specific populations and the patient counseling information.

In Mounjaro, revision 4/22/2026: none of them appear at all. In Zepbound, same revision: none of them appear either, apart from a single entry in the Recent Major Changes table at the top of the document. That entry is the subject of the next section.

That word list and those two revision dates are what make the absence usable. Without them, “the label is silent” is a claim you would have to take on trust.

The warning that was removed²

The one entry reads, verbatim:

Suicidal Behavior and Ideation (Removed) 02/2026

So Zepbound’s label carried a Warnings and Precautions section on suicidal behavior and ideation, and that section was deleted. No trace of its language survives anywhere in the current document.

FDA asked for it. Its safety communication, verbatim:

FDA is requesting that drug application holders remove information regarding the risk of suicidal ideation and behavior (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications that currently include such language. The affected products are Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). This action follows a comprehensive FDA review that found no increased risk of SI/B associated with the use of GLP-1 RA medications.

That also explains why Mounjaro never had the section: the warning only ever sat on the weight-management labels, not on the diabetes-indication one.

Europe reached a similar conclusion earlier, and it is worth being precise about its scope. The PRAC concluded in April 2024 that the evidence did not support a causal association between suicidal and self-injurious thoughts and five named GLP-1 receptor agonists — dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. Tirzepatide was not one of them. It was never part of that review, so nobody can honestly say the EMA cleared it.

What the trials actually measured⁵

A post hoc analysis of SURMOUNT-1, -2 and -3 pooled 4,056 participants and looked specifically at psychiatric safety, using a depression questionnaire and a structured suicidality rating scale. Depressive symptoms improved more on tirzepatide than on placebo. Suicidal ideation was reported in 0.6% of participants in both arms; non-fatal suicidal behavior in 0.1% on tirzepatide and none on placebo.

Several large real-world cohorts point the same way or further: one matched cohort of 16,321 pairs found tirzepatide associated with a 48% lower rate of suicidal ideation or attempts than other anti-obesity medications, and an analysis restricted to people with schizophrenia-spectrum diagnoses found lower rates again. A 2024 European pharmacovigilance review found tirzepatide accounted for 2.3% of psychiatric adverse-event reports across the three drugs it examined, with none of the fatal outcomes.

These are associations from observational data, not proof of an effect. People who are prescribed different drugs differ in ways no matching can fully remove.

The part that disagrees⁵

Two independent real-world cohorts found a small but nominally significant increase in anxiety for tirzepatide compared with semaglutide specifically — not compared with no treatment. One reported a hazard ratio of 1.12 for anxiety in patients without type 2 diabetes; the other found a hazard ratio of 1.052 at two years, which its own authors flagged as warranting caution given how many comparisons were run.

Both are retrospective, both are susceptible to residual confounding, and both sit against a randomized post hoc analysis that found no such signal. They are here anyway. A page that showed you only the findings pointing one way would be leaving out the part you would most want to raise with a prescriber.

There is also a three-patient case series describing loss of motivation and pleasure at a 15 mg dose, resolving when the dose was reduced. Three patients is three patients — it is a hypothesis, not a rate.

The study that is not about this drug⁵

If you search this question you will meet a widely cited 2024 study in a major journal on GLP-1 medicines and suicidal ideation, often presented as being about tirzepatide. It is not. It studied semaglutide, exclusively — and it found a lower risk, not a higher one. Both halves of that sentence get lost when the study is retold.

What a compounded vial changes⁶

One further caveat, which is a fact about the sources rather than the drug: the manufacturer’s medical-information page still describes the suicidality warning as current. Its stated review date is May 2025, which predates the February 2026 label change. Where that page and the label disagree, the label is the label.

Where to take this⁷

To a prescriber, and worth raising at the first appointment rather than later if you have a psychiatric history — the SURMOUNT trials excluded people with significant active or unstable major depressive disorder or other severe psychiatric illness in the previous two years, so the reassuring trial numbers above were not measured in that group.

If what you are actually noticing is exhaustion rather than mood, the label does document that: what it reports about fatigue. If you are weighing this against the approved product, the difference is set out in compounded versus Zepbound.